Drug intelligence / Profile preview

IMX101 (Imunexus)

Development stage: Preclinical
Lead developer: Imunexus
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IMX101 is a preclinical bispecific antibody being developed by Imunexus Therapeutics for the treatment of small cell lung cancer (SCLC). The drug is engineered using the company's proprietary imunexin™ platform, which involves fusing an immune-activating protein (an 'imunexin') to an existing SCLC-specific monoclonal antibody. This design aims to convert a standard antibody into a multispecific therapeutic that can simultaneously bind to tumor cells and trigger a localized immune response. As of early 2024, the specific molecular targets for the SCLC-binding arm and the immune-activating component remain undisclosed.

Targets

DLL3 (Delta-like ligand 3)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on IMX101 (Imunexus).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMX101 (Imunexus).

Explore the full profile